Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Cash & Equivalents (2020 - 2025)

HCW Biologics (HCWB) has disclosed Cash & Equivalents for 6 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 9.69% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Sep 2025, up 9.69%, and an annual FY2024 reading of $4.7 million, up 30.03% over the prior year.
  • Cash & Equivalents was $1.1 million for Q3 2025 at HCW Biologics, down from $2.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $29.2 million in Q4 2022 and bottomed at $82723.0 in Q2 2024.
  • Average Cash & Equivalents over 5 years is $9.6 million, with a median of $4.7 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents tumbled 99.5% in 2024, then soared 2848.35% in 2025.
  • Year by year, Cash & Equivalents stood at $11.7 million in 2021, then surged by 148.87% to $29.2 million in 2022, then tumbled by 87.69% to $3.6 million in 2023, then skyrocketed by 30.03% to $4.7 million in 2024, then plummeted by 76.53% to $1.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for HCWB at $1.1 million in Q3 2025, $2.4 million in Q2 2025, and $590524.0 in Q1 2025.